NCT03402464

Icotinib Combined With Dihydroaremisinin (DHA) Therapy in Patients With Advanced NSCLC

Icotinib Combined With Dihydroaremisinin (DHA) Therapy in Patients With Advanced Gradually Progressed NSCLC After First-line Icotinib: an Open-label, Single-arm, Multicenter Phase II Study

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Peking University Cancer Hospital & Institute · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The study was to evaluate the safety, PFS and ORR of icotinib/dihydroaremisinin (DHA)-based combination therapy in EGFR-mutated, advanced NSCLC patients who have gradually progressed disease after first-line icotinib treatment.

Conditions

• EGFR Positive Non-Small Cell Lung Cancer,Adenocarcinoma

Interventions

Type	Name	Description
DRUG	Icotinib combined dihydroaremisinin	Icotinib should be taken by the patients continuously until disease progressed or intolerable toxicity. On day 1-3, oral dihydroaremisinin was given at 20mg per day, the dose of dihydroaremisinin is increased to 40mg daily on day 4 to 6, and 80mg twice daily until disease progressed or intolerable toxicity.

Timeline

• Start date: 2018-01-01
• Primary completion: 2019-06-01
• Completion: 2020-09-20
• First posted: 2018-01-18
• Last updated: 2018-01-18

Locations

1 site across 1 country: China